Table 4.
Comparison between pre- and post-rituximab therapy.
| No. | mRS before RTX | Best mRS after RTX | CD19+ B cell before RTX, (%) | CD19+ B cell at 1 week after initial infusion, (%) | CD19+ B cell at 4 weeks after initial infusion, (%) | CD19+ B cell at the last follow-up, (%) | Outcome |
|---|---|---|---|---|---|---|---|
| 1 | 3 | 0 | 17.00 | 11.00 | 1.00 | 16.00 | Complete recovery |
| 2 | 4 | 1 | 27.00 | 0.50 | 0.00 | 22.00 | Partial recovery |
| 3 | 4 | 1 | 27.60 | 0.20 | 0.05 | 0.03 | Death |
| 4 | 5 | 0 | 28.00 | 2.00 | 0.70 | 6.20 | Complete recovery |
| 5 | 3 | 3 | 16.60 | 0.07 | 0.03 | 0.05 | No response |
| 6 | 3 | 1 | 45.00 | 1.00 | 0.03 | 0.03 | Death |
| 7 | 3 | 0 | 25.40 | 0.93 | 0.02 | 0.13 | Complete recovery |
| 8 | 4 | 0 | 22.90 | 0.10 | 0.05 | 17.00 | Complete recovery |